menu
    • menu
    [{"orgOrder":0,"company":"Merck Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Abituzumab","moa":"Integrin alpha-V\/beta-6 | Integrin alpha-V\/beta-5 | Integrin alpha-V\/beta-1 | Integrin alpha-V\/beta-8 | Integrin alpha-V\/beta-3","graph1":"Oncology","graph2":"Phase I","graph3":"Merck Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Merck Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck Group \/ Undisclosed"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Abituzumab","moa":"Integrin alpha-V\/beta-6 | Integrin alpha-V\/beta-5 | Integrin alpha-V\/beta-1 | Integrin alpha-V\/beta-8 | Integrin alpha-V\/beta-3","graph1":"Oncology","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EMD Serono \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Undisclosed"},{"orgOrder":0,"company":"EMD Serono","sponsor":"Merck Group","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Abituzumab","moa":"Integrin alpha-V\/beta-6 | Integrin alpha-V\/beta-5 | Integrin alpha-V\/beta-1 | Integrin alpha-V\/beta-8 | Integrin alpha-V\/beta-3","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"EMD Serono","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EMD Serono \/ Merck Group","highestDevelopmentStatusID":"8","companyTruncated":"EMD Serono \/ Merck Group"},{"orgOrder":0,"company":"SFJ Pharmaceuticals","sponsor":"SFJ Pharmaceuticals | Merck Group | AIO-Studien-gGmbH | Academic and Community Cancer Research United","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Abituzumab","moa":"Integrin alpha-V\/beta-6 | Integrin alpha-V\/beta-5 | Integrin alpha-V\/beta-1 | Integrin alpha-V\/beta-8 | Integrin alpha-V\/beta-3","graph1":"Oncology","graph2":"Phase II","graph3":"SFJ Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SFJ Pharmaceuticals \/ SFJ Pharmaceuticals | Merck Group | AIO-Studien-gGmbH | Academic and Community Cancer Research United","highestDevelopmentStatusID":"8","companyTruncated":"SFJ Pharmaceuticals \/ SFJ Pharmaceuticals | Merck Group | AIO-Studien-gGmbH | Academic and Community Cancer Research United"}]

    Find Clinical Drug Pipeline Developments & Deals for Abituzumab

    Menu

    Abituzumab

    DEVELOPMENTS

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SFJ Pharmaceuticals

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            SFJ Pharmaceuticals

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abituzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : SFJ Pharmaceuticals | Merck Group | AIO-Studien-gGmbH | Academic and Community Cancer Research United

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.

                            Details : Abituzumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 28, 2018

                            Lead Product(s) : Abituzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : SFJ Pharmaceuticals | Merck Group | AIO-Studien-gGmbH | Academic and Community Cancer Research United

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EMD Serono

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            EMD Serono

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abituzumab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Abituzumab in SSc-ILD

                            Details : Abituzumab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lung Diseases, Interstitial.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 20, 2016

                            Lead Product(s) : Abituzumab

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Merck Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            EMD Serono

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            EMD Serono

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abituzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

                            Details : EMD 525797 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            May 26, 2011

                            Lead Product(s) : Abituzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Merck Group

                            Germany arrow
                            Global ChemShow
                            Not Confirmed

                            Merck Group

                            Germany arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Abituzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of EMD525797 in Solid Tumor Patients in Japan

                            Details : EMD 525797 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            April 01, 2011

                            Lead Product(s) : Abituzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth